Hoth Therapeutics Inc. (HOTH) shareholders have not approved the reverse stock split

0

News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.


Hoth Therapeutics Inc. (NASDAQ: HOTH) disclosed:

On June 15, 2022, Hoth Therapeutics, Inc. (the “Company”) originally held its 2022 annual meeting of shareholders (the “Annual Meeting”) for the purpose of adjourning the Annual Meeting to June 23, 2022 in order to allow more time to solicit proxies and obtain quorum for the annual meeting. On June 23, 2022, the Company reconvened its adjourned annual meeting for the purpose of holding a shareholder vote on Proposals 1, 2, 3 and 4 set forth below. A total of 16,639,708 common shares of the Company, constituting a quorum, were represented in person or by valid proxy at the Annual Meeting.

At the annual meeting, the shareholders of the company (i) re-elected Robb Knie, David Sarnoff, Graig Springer and Wayne Linsley as members of the board of directors of the company until the next annual meeting of shareholders or until their respective successors have been duly elected and qualified, or until the resignation, removal or prior death of such director; (ii) ratified the appointment of Withum Smith+Brown, PC as the independent registered public accounting firm of the Company for the year ended December 31, 2022; and (iii) approved the Company’s 2022 General Equity Incentive Plan.

The proposal to grant discretion to the Board of Directors of the Company to (A) amend the Articles of the Company, as amended, to effect one or more consolidations of the issued and outstanding common shares of the Company in pursuant to which the shares of the Common Shares would be combined and reclassified into one Common Share at a ratio of between 1:2 and 1:20 (the “Share Consolidation”) and (B) arranging for the disposition of fractional interests by shareholders entitled thereto by allowing such shareholders to receive from the Company’s transfer agent, in lieu of any fractional share, the number of ordinary shares rounded up to the next whole number, provided that, (X ) the Company does not carry out any share consolidations which, in the aggregate, exceed 1 for 20, and (Y) any share consolidation is completed on or before June 15, 2023 has not been approved by the required vote of ‘a majority of the issued and remaining shares of the company anding parts. As previously disclosed in a current report on Form 8-K filed by the company with the Securities and Exchange Commission on January 4, 2022, the company has received written notice from Nasdaq that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), indicating that the Company has until June 28, 2022 to regain compliance with the minimum closing bid price requirement, which may be extended for an additional 180 calendar days, subject to Nasdaq’s sole discretion. The Company plans to call a special meeting of shareholders to review the proposed share consolidation and will provide information to its shareholders as it becomes available.

The final results for each of the matters put to a shareholder vote at the annual meeting, as set forth in the company’s definitive proxy statement, filed with the Securities and Exchange Commission on April 27, 2022, are as follows:

Proposal 1. At the annual meeting, the mandates of all current members of the Board of Directors of the Company have expired. The four director nominees have been elected to serve until the next annual meeting of shareholders or until their respective successors have been duly elected and qualified, or until resignation, removal or death. of this administrator. The results of the votes to elect the four directors are as follows:

Administrators For Against Abstentions Broker Non-Votes
Robb Knie 8,706,084 704,122 437,614 6,791,888
David Sarnoff 7,962,975 1,445,023 439,822 6,791,888
Craig Springer 7,884,412 1,525,838 437,570 6,791,888
Wayne Linsley 7,970,575 1,440,825 436,420 6,791,888

-1-

Proposal 2. At the annual meeting, shareholders approved the ratification of the appointment of Withum Smith+Brown, PC (“Withum”) as the registered independent public accounting firm of the Company for the financial year ended. ending December 31, 2022. The result of the votes to approve Withum was as follows:

For Against Abstain
15,189,746 1,017,845 432,117

Proposal 3. At the Annual Meeting, shareholders approved the Corporation’s 2022 Omnibus Stock Incentive Plan (the “2022 Plan”). The result of the 2022 Plan approval votes is as follows:

For Against Abstention Broker No vote
7,580,507 1,884,910 382,403 6,791,888

Proposal 4. At the annual meeting, the shareholders did not approve the share consolidation. The result of the votes to approve the reverse stock split was as follows:

For Against Abstain
13,162,362 3,116,563 360,783

-2-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

Date: June 23, 2022 Hoth Therapeutics, Inc.

/s/Robb Knie
Robb Knie
Chief executive officer

Share.

Comments are closed.